Title : Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.

Pub. Date : 2020 Feb

PMID : 31183631






8 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. osimertinib epidermal growth factor receptor Homo sapiens
2 3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non-small-cell lung cancers (NSCLC) with EGFR mutations. osimertinib epidermal growth factor receptor Homo sapiens
3 3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non-small-cell lung cancers (NSCLC) with EGFR mutations. osimertinib epidermal growth factor receptor Homo sapiens
4 In particular, we assessed the efficacy of osimertinib for NSCLC with EGFR T790 M mutations in patients who were diagnosed with EGFR T790 M mutation by malignant effusion. osimertinib epidermal growth factor receptor Homo sapiens
5 In particular, we assessed the efficacy of osimertinib for NSCLC with EGFR T790 M mutations in patients who were diagnosed with EGFR T790 M mutation by malignant effusion. osimertinib epidermal growth factor receptor Homo sapiens
6 Among 90 patients with EGFR T790 M mutation who started osimertinib treatment after EGFR-TKI failure, 21 were diagnosed from malignant effusions excluding cerebrospinal fluid (F group) and 69 using other methods including tissue biopsies (NF group). osimertinib epidermal growth factor receptor Homo sapiens
7 Among 90 patients with EGFR T790 M mutation who started osimertinib treatment after EGFR-TKI failure, 21 were diagnosed from malignant effusions excluding cerebrospinal fluid (F group) and 69 using other methods including tissue biopsies (NF group). osimertinib epidermal growth factor receptor Homo sapiens
8 The present study showed that the efficacy of osimertinib for NSCLC in which EGFR T790 M mutation is detected by malignant effusion may be less than in EGFR T790 M-mutated NSCLC detected by other methods. osimertinib epidermal growth factor receptor Homo sapiens